Histological changes following the administration of two different chondroitin sulfate products in experimental osteoarthritis models in rats
DOI:
https://doi.org/10.15584/ejcem.2021.1.4Keywords:
chondroitin sulfate, chondroprotection, osteoarthritisAbstract
Introduction. Osteoarthritis (OA) is generally a progressive disease that affects synovial joints, resulting in abnormalities to articular cartilage subchondral bone, synovium, and adjacent soft tissues.
Aim. The purpose of this work was to examine the histological changes in knee cartilage and bone following the administration of two different chondroitin sulfate products in two experimental OA models in rats.
Material and methods. OA was induced in rats by either a single injection of mono-iodoacetate or four once-weekly injections of dexamethasone. 70 adult rats were included: 30 received mono-iodoacetate, 30 received dexamethasone and the 10 remaining controls received no injection. Samples of knee bone and cartilage were then analyzed histologically.
Results. Animals with OA that received CS had significantly less inflammation, improved motor activity, and better analgesia compared with those that did not receive CS, with little difference between products. Histologically, both products reduced the signs of OA and resulted in the activation of regenerative processes of cartilage and bone and stimulation of proliferation and formation of amorphous material.
Conclusion. These results substantiate the importance of using high-quality pharmaceutical-grade CS to ensure optimal efficacy and safety of the final product in patients with OA.
Downloads
References
Lane NE, Brandt K, Hawker G, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthr Cartil. 2011;19:478-482.
Hochberg M, Chevalier X, Henrotin Y, Hunter DJ, Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin. 2013;29:259-267.
Conaghan PG, Kloppenburg M, Schett G, Bijlsma JW. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Ann Rheum Dis. 2014;73:1442-1445.
Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;72:1125-1135.
Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253-263.
Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil. 2010;18,1:28-31.
Schneider H, Maheu E, Cucherat M. Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with Structum®. Open Rheumatol J. 2012;6:183-189.
Martel-Pelletier J, Farran A, Montell E, Verges J, Pelletier JP. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015;20:4277-4289.
Kwan Tat S, Pelletier JP, Mineau F, Duval N, Martel-Pelletier J. Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process. J Rheumatol. 2010;37:656-664.
Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1:CD005614.
Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76:1537-1543.
Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40:1670-1679.
Nosivets DS. Eksperimentalnyie modeli patologii hryaschevoy tkani. Zaporozhskiy meditsinskiy zhurnal. 2019;4(115):554-560.
Nosivets DS. Otsinka vplyvu khondroitynu sulfatu na morfometrychni parametry kolinnoho suhlobu, bolovyi porih ta biokhimichni pokaznyky u shchuriv pry eksperymentalnomu osteoartrozi. Ukr zhurn medytsyny, biolohii ta sportu. 2020;2(24):77-83.
Rukovodstvo po provedeniyu doklinicheskih issledovaniy lekarstvennyih sredstv pod red. prof. Mironova A.N. Ch. 1.- M., 2012;944.
AVMA Guidelines for the Euthanasia of Animals: 2020 Edition - https://www.avma.org/sites/default/files/2020-01/2020_Euthanasia_Final_1-15-20.pdf
Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003;31:619-624.
Guidelines for experimental (preclinical) study of new pharmacological substances. Endorsed by corresponding member of RAMS prof. R. U. Khabrieva. 2005:425.
Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthr Cartil. 2003;11:433-441.
Li L, Li Y, Feng D, et al. Preparation of low molecular weight chondroitin sulfates, screening of a high anti-complement capacity of low molecular weight chondroitin sulfate and its biological activity studies in attenuating osteoarthritis. Int J Mol Sci. 2016;17:E1685.
Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Calatroni A. Chondroitin-4-sulphate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice. Osteoarthr Cartil. 2008;16:1474-1483.
Taniguchi S, Ryu J, Seki M, Sumino T, Tokuhashi Y, Esumi M. Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. J Orthop Res. 2012;30:673-678.
Largo R, Roman-Blas JA, Moreno-Rubio J, et al. Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. Osteoarthr Cartil. 2010;18,1:17-23.
Xiao P, Dong M, Hong X, et al. Effect of cartilage protective agents on histopathological, histochemical features of articular cartilage and serum level of aggrecan in Hartley guinea pigs. Wei Sheng Yan Jiu. 2008;37:171-174.
Caraglia M, Beninati S, Giuberti G, et al. Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice. Exp Mol Med. 2005;37:476-481.
Permuy M, Guede D, Lopez-Pena M, Munoz F, Caeiro JR, Gonzalez-Cantalapiedra A. Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. BMC Musculoskelet Disord. 2015;16:120.
Torelli SR, Rahal SC, Volpi RS, Sequeira JL, Grassioto IQ. Histopathological evaluation of treatment with chondroitin sulphate for osteoarthritis induced by continuous immobilization in rabbits. J Vet Med A Physiol Pathol Clin Med. 2005;52:45-51.
Chen L, Ling PX, Jin Y, Zhang TM. Hyaluronic acid in combination with chondroitin sulfate and hyaluronic acid improved the degeneration of synovium and cartilage equally in rabbits with osteoarthritis. Drug Discov Ther. 2011;5:190-194.
Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung. 1991;41:768-772.
Conte A, Palmieri L, Segnini D, Ronca G. Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat. Drugs Exp Clin Res. 1991;17:27-33.
Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995;45:918-925.
Rivera F, Bertignone L, Grandi G. et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. J Orthopaed Traumatol. 2016;17:27-33.
Henrotin Y, Hauzeur J-P, Bruel P, Appelboom T. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Research Notes. 2012; 5:407-419.
Fonsi M, Amrani AI, Gervais F, Vincent P. Intra-articular hyaluronic acid and chondroitin sulfate: pharmacokinetic investigation in osteoarthritic rat models. Curr Ther Res Clin Exp. 2020;92:100573.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
